On Tuesday, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) opened lower -0.39% from the last session, before settling in for the closing price of $41.12. Price fluctuations for RARE have ranged from $31.52 to $54.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 63.06% over the past five years. Company’s average yearly earnings per share was noted 19.23% at the time writing. With a float of $84.86 million, this company’s outstanding shares have now reached $90.57 million.
Let’s look at the performance matrix of the company that is accounted for 1276 employees.
Ultragenyx Pharmaceutical Inc. (RARE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ultragenyx Pharmaceutical Inc. is 6.30%, while institutional ownership is 89.68%. The most recent insider transaction that took place on Jun 12 ’24, was worth 441,270. In this transaction EVP and Chief Legal Officer of this company sold 9,806 shares at a rate of $45.00, taking the stock ownership to the 57,981 shares. Before that another transaction happened on Jun 10 ’24, when Company’s Director sold 1,737 for $41.10, making the entire transaction worth $71,391. This insider now owns 7,248 shares in total.
Ultragenyx Pharmaceutical Inc. (RARE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 19.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Trading Performance Indicators
Check out the current performance indicators for Ultragenyx Pharmaceutical Inc. (RARE). In the past quarter, the stock posted a quick ratio of 2.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.03, a number that is poised to hit -1.67 in the next quarter and is forecasted to reach -5.19 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) saw its 5-day average volume 1.29 million, a positive change from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 83.84%. Additionally, its Average True Range was 1.75.
During the past 100 days, Ultragenyx Pharmaceutical Inc.’s (RARE) raw stochastic average was set at 22.46%, which indicates a significant decrease from 45.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.38% in the past 14 days, which was higher than the 45.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.38, while its 200-day Moving Average is $42.47. Nevertheless, the first resistance level for the watch stands at $41.41 in the near term. At $41.86, the stock is likely to face the second major resistance level. The third major resistance level sits at $42.65. If the price goes on to break the first support level at $40.18, it is likely to go to the next support level at $39.39. The third support level lies at $38.94 if the price breaches the second support level.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Key Stats
There are currently 83,133K shares outstanding in the company with a market cap of 3.71 billion. Presently, the company’s annual sales total 434,250 K according to its annual income of -606,640 K. Last quarter, the company’s sales amounted to 108,830 K and its income totaled -170,680 K.
